Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 2/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703595 | 0.87 | CYP3A4 (0.58) | KDRSMN1; SMN2CNR1KMT2ACYP3A4 | |
| SCHEMBL3442461 | 0.86 | CYP3A4 (0.60) | KDRMAPTLMNAHTTGAA | |
| SCHEMBL3443154 | 0.85 | CYP3A4 (0.58) | KDRSMN1; SMN2LMNATP53CNR1 | |
| SCHEMBL3443290 | 0.84 | TP53 (0.54) | KDRMAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL1703159 | 0.82 | KDR (0.60) | KDRMAPTHTTRAB9AMEN1 | |
| SCHEMBL1703490 | 0.81 | KIT (0.57) | KDRMEN1KMT2ACYP3A4CYP3A5 | |
| SCHEMBL1703172 | 0.80 | KDR (0.56) | KDRMAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL1703153 | 0.79 | KDR (0.57) | KDRMAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL1703220 | 0.79 | KDR (0.53) | KDRSMN1; SMN2GAAALDH1A1RAB9A | |
| SCHEMBL1162717 | 0.76 | KDM4E (0.61) | MAPTSMN1; SMN2LMNAHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807424-B1 | NOVEL KINASE INHIBITORS | ABBOTT LAB (US) | 2012-04-18 | — | — | EP | disclosed |
| US-7812166-B2 | Kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-10-12 | — | — | US | disclosed |
| US-20060178378-A1 | Novel kinase inhibitors | ABBVIE INC. | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178378-A1 | Novel kinase inhibitors | ABL1, MAP3K19, MAP3K20 | KDR 434/4885MAPT 2564/4885SMN1; SMN2 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.